<DOC>
	<DOC>NCT00248131</DOC>
	<brief_summary>This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802. During this extension study, all patients will receive open-label treatment of octreotide acetate in microspheres every 4 weeks for 2 years for the treatment of moderately severe to severe NPDR and low risk PDR.</brief_summary>
	<brief_title>Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>written informed consent provided prior to participation in the extension study successful completion of study CSMS995 0802 willingness to comply with all study requirements more than 8 weeks interval since the completion of study CSMS995 0802 premature discontinuation from study CSMS995 0802 Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Diabetic retinopathy, octreotide acetate in microspheres</keyword>
</DOC>